Stockscreener 앱 받기
5.76
3.03%
-0.18
시장 영업 전:
5.73
-0.03
-0.52%
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
ARS Pharmaceuticals Inc (SPRY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ARS Pharmaceuticals Inc (SPRY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BlackRock discloses 5.3% ownership of ARS Pharmaceuticals (SPRY) common stock - Stock Titan
SPRY|ARS Pharmaceuticals Inc|Price:6.110|Chg%:+0.170 - TradingKey
TradingKey - TradingKey
ARS Pharmaceuticals Inc (SPRY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ARS Pharmaceuticals Inc (SPRY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ARS Pharmaceuticals Inc (SPRY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
(SPRY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ARS passes the ball to Drew Brees in Neffy awareness campaign - Fierce Pharma
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo
Ars Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
ARS Pharmaceuticals, Inc. 8-K SEC Filing July 2026 – Company Info, Stock Symbol SPRY, and Nasdaq Listing - Minichart
ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc.SPRY - PR Newswire
Donn Casale Net Worth (2026) - GuruFocus
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Connect - ACCESS Newswire
Pomerantz LLP investigates ARS Pharmaceuticals for possible securities fraud after stock drops 24%. - Pluang
Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5% - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-07-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What's Going on With ARS Pharma Stock Thursday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
ARS Pharmaceuticals appoints Donn Casale as CEO - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirt - The National Law Review
ARS Pharmaceuticals: CEO Richard Lowenthal Will No Longer Serve as Employee and Officer, Effective July 6 - Moomoo
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Investors to Connect - ACCESS Newswire
ARS Pharmaceuticals appoints new CEO - MSN
ARS Pharmaceuticals Announces CEO Succession - Investing News Network
ARS Pharmaceuticals Names Casale CEO, Succeeding Co-Founder Lowenthal - Moomoo
ARS Pharmaceuticals names Donn Casale as new CEO By Investing.com - Investing.com South Africa
ARS Pharmaceuticals names Donn Casale as new CEO - Investing.com
ARS Pharmaceuticals stock falls as CEO Lowenthal steps down - Investing.com
ARS Pharmaceuticals Names Donn Casale as CEO as Richard Lowenthal Departs - Moomoo
ARS Pharmaceuticals: Donn Casale, Pres, Appointed CEO and Director >SPRY - Moomoo
Donn Casale becomes ARS Pharmaceuticals (SPRY) CEO and joins board through 2029 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
ARS Pharmaceuticals Appoints Donn Casale CEO, Succeeds Co-Founder Richard Lowenthal - Quiver Quantitative
ARS Pharmaceuticals stock plunges 23% after Nef... - Pluang
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals, Inc. (SPRY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) Securities Fraud InvestigationLevi & Korsinsky - Morningstar
Bronstein, Gewirtz & Grossman, LLC Encourages ARS Pharmaceuticals - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (SPRY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceu - The National Law Review
SPRY Should I Buy - Intellectia AI
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ARS Pharmaceuticals (SPRY) President awarded 898,456 long-term stock options - Stock Titan
ARS Pharmaceuticals plunges 23% as Neffy fails to secure insurance coverage - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
1.97%
0.83%
자본화:
|
볼륨(24시간):